<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7810">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886899</url>
  </required_header>
  <id_info>
    <org_study_id>200-0002</org_study_id>
    <nct_id>NCT00886899</nct_id>
  </id_info>
  <brief_title>Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs)</brief_title>
  <acronym>FAST-CTOs</acronym>
  <official_title>Facilitated Antegrade Steering Technique in Chronic Total Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BridgePoint Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BridgePoint Medical</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-randomized, multicenter study in subjects with coronary artery chronic
      total occlusions (CTOs). Published results of safety and effectiveness of conventional
      techniques will be used for comparison. Enrollment of up to 149 subjects with a CTO
      refractory to currently marketed guidewire use and meeting all inclusion/exclusion criteria
      at up to 15 US clinical sites. Hypothesis is that the BridgePoint Medical System is safe and
      effective in treating coronary CTOs compared to CTO literature.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Intraprocedural</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the ability of the BridgePoint Medical System to successfully facilitate placement of a guidewire beyond a chronic total occlusion (CTO) in the true vessel lumen in cases that were otherwise refractory to treatment with a currently marketed guidewire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>30-day Major Adverse Cardiac Event (MACE) Rate</measure>
    <time_frame>30 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Defined as cardiac death, Q-wave and non-Q-wave [total creatinine kinase (CK) &gt;2x upper limit of normal with a positive myocardial band (MB) fraction] myocardial infarction (MI), target lesion revascularization (TLR), and emergency bypass surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>Intraprocedural</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minus any time to determine CTO was refractory to standard guidewire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Procedural Fluoroscopy Time</measure>
    <time_frame>Intraprocedural</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minus any time to determine CTO was refractory to standard guidewire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Coronary Artery Chronic Total Occlusion</condition>
  <arm_group>
    <arm_group_label>BridgePoint Medical System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Recanalization of a coronary chronic total occlusion</intervention_name>
    <description>Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement</description>
    <arm_group_label>BridgePoint Medical System</arm_group_label>
    <other_name>CrossBoss Catheter</other_name>
    <other_name>Stingray Catheter</other_name>
    <other_name>Stingray Guidewire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suitable candidate for non-emergent, coronary angioplasty

          -  documented coronary CTO lesion with the following characteristics: a) Thrombolysis in
             Myocardial Infarction (TIMI) 0 flow for at least 90 days; b) satisfactory distal
             vessel visualization; and c) refractory to currently marketed guidewire crossing via
             1 of the following: 1. previous failed attempt to cross CTO within the past 12
             months; or 2. unsuccessful CTO crossing w/ guidewire (10-15 min fluoro time); or 3.
             attempt to cross CTO w/ guidewire results in subintimal guidewire

          -  angina or ischemia caused by the occluded artery

          -  at least 18 years of age

          -  Body Mass Index (BMI) &lt; 40

          -  left ventricle ejection fraction &gt; 20%

          -  sign the Informed Consent Form

        Exclusion Criteria:

          -  saphenous vein graft (SVG) CTO or an in-stent CTO

          -  aorto-ostial CTO location. (Ostial bifurcation origins may be considered)

          -  intolerance to aspirin or a neutropenic response to Ticlopidine/Clopidogrel

          -  appearance of thrombus or intraluminal filling defects

          -  severe cerebrovascular disease (history of stroke or TIA within 1 month)

          -  cardiac intervention within two weeks of the procedure

          -  renal insufficiency (serum creatinine of &gt; 2.3 mg/dl)

          -  active gastrointestinal bleeding

          -  active infection or fever that may be due to infection

          -  life expectancy &lt; 2 years due to other illnesses

          -  significant anemia (hemoglobin &lt; 8.0 mg / dl)

          -  severe uncontrolled systemic hypertension

          -  severe electrolyte imbalance

          -  anaphylaxis to angiographic contrast media unless appropriately medicated

          -  congestive heart failure [New York Heart Association (NYHA) Class IV]

          -  unstable angina requiring emergent percutaneous transluminal coronary angioplasty
             (PTCA) or coronary artery bypass graft (CABG)

          -  recent myocardial infarction (MI)(within the past two weeks)

          -  uncontrolled diabetes

          -  participation in another investigational protocol

          -  unwillingness or inability to comply with any protocol requirements

          -  pregnant or nursing

          -  extensive dissection from refractory guidewire use

          -  crossing CTO (true lumen) w/ guidewire within 10-15 min of fluoro time
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Whitlow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Heart &amp; Vascular Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Cardiovascular Consultants</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute, Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - St. Mary's Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid America Heart Institute, St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 15, 2012</lastchanged_date>
  <firstreceived_date>April 21, 2009</firstreceived_date>
  <firstreceived_results_date>February 21, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTO</keyword>
  <keyword>chronic total occlusion</keyword>
  <keyword>CAD</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>interventional cardiology</keyword>
  <keyword>revascularization</keyword>
  <keyword>recanalization</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BridgePoint Medical System</title>
          <description>Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BridgePoint Medical System</title>
          <description>Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="147"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63.3" spread="9.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="127"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="147"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Technical Success</title>
        <description>Defined as the ability of the BridgePoint Medical System to successfully facilitate placement of a guidewire beyond a chronic total occlusion (CTO) in the true vessel lumen in cases that were otherwise refractory to treatment with a currently marketed guidewire</description>
        <time_frame>Intraprocedural</time_frame>
        <safety_issue>No</safety_issue>
        <population>Three participants had two CTOs, so there were a total of 150 CTOs in 147 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>BridgePoint Medical System</title>
            <description>Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="147"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of CTOs analyzed</title>
            <units>CTOs</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Technical Success</title>
            <description>Defined as the ability of the BridgePoint Medical System to successfully facilitate placement of a guidewire beyond a chronic total occlusion (CTO) in the true vessel lumen in cases that were otherwise refractory to treatment with a currently marketed guidewire</description>
            <units>percentage of CTOs</units>
            <param>Number</param>
            <dispersion>90% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="77" lower_limit="70" upper_limit="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>30-day Major Adverse Cardiac Event (MACE) Rate</title>
        <description>Defined as cardiac death, Q-wave and non-Q-wave [total creatinine kinase (CK) &gt;2x upper limit of normal with a positive myocardial band (MB) fraction] myocardial infarction (MI), target lesion revascularization (TLR), and emergency bypass surgery.</description>
        <time_frame>30 Days</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes 21 patients with &quot;early&quot; (&lt;30 day) follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>BridgePoint Medical System</title>
            <description>Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="147"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>30-day Major Adverse Cardiac Event (MACE) Rate</title>
            <description>Defined as cardiac death, Q-wave and non-Q-wave [total creatinine kinase (CK) &gt;2x upper limit of normal with a positive myocardial band (MB) fraction] myocardial infarction (MI), target lesion revascularization (TLR), and emergency bypass surgery.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>90% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>All participants</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.8" lower_limit="2.3" upper_limit="8.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patients with at least 30-days follow-up (n=136)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.1" lower_limit="2.5" upper_limit="9.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Procedure Time</title>
        <description>Minus any time to determine CTO was refractory to standard guidewire</description>
        <time_frame>Intraprocedural</time_frame>
        <safety_issue>No</safety_issue>
        <population>Procedure time data for two participants was not available.</population>
        <group_list>
          <group group_id="O1">
            <title>BridgePoint Medical System</title>
            <description>Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="145"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Procedure Time</title>
            <description>Minus any time to determine CTO was refractory to standard guidewire</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105" spread="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Procedural Fluoroscopy Time</title>
        <description>Minus any time to determine CTO was refractory to standard guidewire</description>
        <time_frame>Intraprocedural</time_frame>
        <safety_issue>No</safety_issue>
        <population>Fluoroscopy time was not available for two participants</population>
        <group_list>
          <group group_id="O1">
            <title>BridgePoint Medical System</title>
            <description>Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="145"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Procedural Fluoroscopy Time</title>
            <description>Minus any time to determine CTO was refractory to standard guidewire</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44" spread="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BridgePoint Medical System</title>
          <description>Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Non-Q-Wave Myocardial Infarction (NQWMI)</sub_title>
                <description>Defined as total serum creatinine kinase (CK) greater than twice the upper limit of normal with greater than the upper limit of normal myocardial band (CK-MB)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Arrhythmia Requiring Treatment</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Vascular Accident/Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Perforation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Enzyme Elevation</sub_title>
                <description>Enzyme elevation that did not fit the definition of NQWMI</description>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Untreated Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Puncture Site Complication</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Non-Target Vessel Treatment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Includes but not limited to: chest pain, hypotension, radiation burn, pulmonary embolism, dermatitis, vomiting, vasovagal reaction, and heart murmur.</description>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Clinical Affairs</name_or_title>
      <organization>BridgePoint Medical</organization>
      <phone>763-225-8500</phone>
      <email>jschultz@bridgepointmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
